Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)

被引：0

作者：

Raab, M. -S. ^{[1
]}

Richardson, P. G. ^{[2
]}

Ocio, E. M. ^{[3
]}

Raje, N. ^{[4
]}

Gregory, T. ^{[5
]}

White, D. ^{[6
,7
]}

Oriol, A. ^{[8
,9
]}

Sandhu, I. ^{[10
]}

LeBlanc, R. ^{[11
]}

Rodriguez Valdes, C. ^{[12
]}

Trudel, S. ^{[13
]}

Waesch, R. ^{[14
]}

Perrot, A. ^{[15
]}

Bahlis, N. J. ^{[16
]}

Zhou, Z. ^{[17
]}

Lamba, M. ^{[17
]}

Amatangelo, M. ^{[17
]}

Civardi, T. ^{[18
]}

Katz, J. ^{[17
]}

Maciag, P. ^{[17
]}

Peluso, T. ^{[18
]}

Dimopoulos, M. A. ^{[19
]}

机构：

[1] Univ Klinikum Heidelberg, Heidelberg, Germany

[2] Dana Farber Canc Inst, Boston, MA USA

[3] Hosp Univ Marques De Valdecilla IDIVAL, Santander, Spain

[4] Massachusetts Gen Hosp, Boston, MA USA

[5] Colorado Blood Canc Inst, Denver, CO USA

[6] Dalhousie Univ, Halifax, NS, Canada

[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[8] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[9] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain

[10] Univ Alberta, Edmonton, AB, Canada

[11] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[12] Wake Forest Baptist Hlth, Winston Salem, NC USA

[13] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[14] Univ Klinikum Freiburg, Freiburg, Germany

[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Celgene Int Sarl, Bristol Myers Squibb Co, Boudry, Switzerland

[19] Alexandria Gen Hosp, Athens, Greece

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P308

引用

页码：86 / 86

页数：1

共 50 条

[21] Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma
Wong, Lilly
Lamba, Manisha
Nunez, Maria Dolores Jimenez
Bauer, Daniel
Richardson, Paul G.
Bahlis, Nizar J.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Rodriguez-Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Pourdehnad, Michael
Pierce, Daniel W.
BLOOD, 2020, 136
[22] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
Lonial, Sagar
Popat, Rakesh
Hulin, Cyrille
Jagannath, Sundar
Oriol, Albert
Richardson, Paul G.
Facon, Thierry
Weisel, Katja
Larsen, Jeremy T.
Minnema, Monique C.
Abdallah, Al-Ola
Badros, Ashraf Z.
Knop, Stefan
Stadtmauer, Edward A.
Chen, Min
Nguyen, Tuong Vi
Amin, Alpesh
Kueenburg, Elisabeth
Peluso, Teresa
van de Donk, Niels W. C. J.
BLOOD, 2021, 138
[23] A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)
Chari, Ajai
Htut, Myo
Zonder, Jeffrey
Fay, Joseph W.
Jakubowiak, Andrzej J.
Harrison, Beverly
Lau, Kenneth
Hilder, Brandi
Ptaszynski, Ann
Rush, Selena A.
Kaufman, Jonathan L.
Burt, Steven Michael
BLOOD, 2013, 122 (21)
[24] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
van de Donk, Niels W. C. J.
Popat, Rakesh
Larsen, Jeremy
Minnema, Monique C.
Jagannath, Sundar
Oriol, Albert
Zonder, Jeffrey A.
Richardson, Paul G.
Rodriguez Otero, Paula
Badros, Ashraf Z.
Stadtmauer, Edward
Bringhen, Sara
Campagnaro, Erica
Siegel, David S.
Gamberi, Barbara
Gironella Mesa, Mercedes
Sonneveld, Pieter
Tuong Vi Nguyen
Di Micco, Antonia
Sorrell, April
Chen, Min
Amatangelo, Michael
Kueenburg, Elisabeth
Lonial, Sagar
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 17 - 18
[25] CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in PreClinical Multiple Myeloma
Bjorklund, Chad C.
Amatangelo, Michael
Kang, Jian
Chiu, Hsiling
Mukhopadhyay, Archana
Wollerman, Krista
Pourdehnad, Michael
Hagner, Patrick
Thakurta, Anjan
BLOOD, 2021, 138
[26] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
Richardson, Paul
Jagannath, Sundaf
Raje, Noopur
Jakubowiak, Andrzej
Lonial, Sagar
Ghobrial, Irene
Schlossman, Robert
Mazumder, Amitabha
Munshi, Nikhil
Colson, Kathleen
McKenney, Mary
Farrell, Melissa
Lunde, Laura
Giove, Lawrence
Kaster, Sarah
Mitsiades, Constantine
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth
BLOOD, 2007, 110 (11) : 797A - 797A
[27] A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Chari, A.
Htut, M.
Zonder, J.
Fay, J.
Jakubowiak, A.
Harrison, B.
Lau, K.
Burt, S.
Hilder, B.
Ptaszynski, A. M.
Rush, S.
Kaufman, J.
HAEMATOLOGICA, 2014, 99 : 113 - 113
[28] First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
van de Donk, Niels W. C. J.
Popat, Rakesh
Zonder, Jeffrey A.
Minnema, Monique C.
Larsen, Jeremy
Tuong Vi Nguyen
Chen, Min S.
Bensmaine, Amine
Cota, Mariana
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
van de Donk, Niels
White, Darrell
Lipe, Brea
Khan, Abdullah
Niesvizky, Ruben
Oriol, Albert
Mesa, Mercedes Gironella
Anwer, Faiz
Bhutani, Manisha
McClune, Brian
Singhal, Seema
Cheng, Yiming
Hamada, Izumi
Jin, Kexin
Solomon, Thomas
Hong, Kevin
Amin, Alpesh
Maciag, Paulo
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S214 - S215
[30] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Schlossman, R.
Munshi, N.
Knight, R.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →